Comparative Efficacy & Tolerability of Pharmacological & Somatic Interventions in Adult Patients with Treatment-Resistant Depression




Curated By TMS Solutions on Sep 16, 2017 1:16:00 AM
Curated By TMS Solutions

TITLE
Comparative Efficacy and Tolerability of Pharmacological and Somatic Interventions in Adult Patients with Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis 

AUTHORS
Papadimitropoulou K; Vossen C; Karabis A; Donatti C; Kubitz N.

SOURCE
Current Medical Research & Opinion. 33(4):701-711, 2017 Apr.

OBJECTIVE
Major depressive disorder (MDD) affects about 10-15% of the general population in a lifetime. A considerable number of patients fail to achieve full symptom remission despite adequate treatment and are considered treatment resistant (TRD). The current study compared the relative efficacy and tolerability of pharmacological and somatic TRD interventions by means of a Bayesian network meta-analysis.

RESEARCH DESIGN AND METHODS
An electronic literature search of MEDLINE, MEDLINE In-Process, EMBASE, PsycInfo, EconLit and Cochrane Library databases for trials published between September 2003 and September 2014 was conducted. Key outcomes extracted were disease severity change from baseline, response and remission rates at various timepoints and discontinuation due to adverse events.

RESULTS
Of the 3876 abstracts identified, 31 publications/randomised controlled trials (RCTs) were included in the analysis; 19 RCTs investigating 13 pharmacological interventions and 12 RCTs investigating electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS). The evidence synthesis investigating efficacy outcomes of TRD treatments demonstrated superior efficacy for ketamine compared to pharmacological and somatic interventions at 2 weeks after treatment initiation. At 4, 6 and 8 weeks, quetiapine augmentation (800mg/day) and risperidone augmentation were found to be the first and second best treatments, respectively. Networks were small for response rate and remission rate outcomes at most timepoints. The most tolerable treatment was lamotrigine augmentation showing a comparable profile to placebo/sham.

CONCLUSIONS
This analysis revealed scarcity of long-term data on sustained remission that would allow a comparative long-term efficacy assessment. Key limitations of the analysis can be considered the search timeframe and the use of mapping formula for the depression scores.

Topic of this Article:

Topics: Medical Aspects


Posts by Topic

Subscribe to Solute Email Updates